The Plasminogen Activator Inhibitor 1 pipeline drugs market research report outlays comprehensive information on the Plasminogen Activator Inhibitor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Plasminogen Activator Inhibitor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Oncology, Cardiovascular, and Respiratory which include the indications Inflammatory Bowel Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Oncology, Melanoma, Thrombosis, Arterial Thrombosis, Idiopathic Pulmonary Fibrosis, and Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). It also reviews key players involved in Plasminogen Activator Inhibitor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Plasminogen Activator Inhibitor 1 pipeline targets constitutes close to 17 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 1, 3, and 2 respectively. Similarly, the universities portfolio in Phase III, and Preclinical comprises 1, and 7 molecule.
Plasminogen Activator Inhibitor 1 overview
Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).
For a complete picture of Plasminogen Activator Inhibitor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
